Pages that link to "Q34096483"
Jump to navigation
Jump to search
The following pages link to Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation (Q34096483):
Displaying 50 items.
- Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals (Q26773321) (← links)
- Extracellular vesicles from infected cells: potential for direct pathogenesis (Q26779430) (← links)
- Animal models for the study of HCV (Q26797836) (← links)
- Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design (Q26801759) (← links)
- Advances in experimental systems to study hepatitis C virus in vitro and in vivo (Q26851652) (← links)
- Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization (Q26864485) (← links)
- Viral quasispecies evolution (Q27013917) (← links)
- Neutralizing antibody response to hepatitis C virus (Q27027484) (← links)
- Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape (Q27678252) (← links)
- Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry (Q28478310) (← links)
- A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission (Q28488372) (← links)
- Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution (Q28659586) (← links)
- Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization (Q28731355) (← links)
- Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. (Q30386551) (← links)
- Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection (Q30407004) (← links)
- Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission (Q30541733) (← links)
- A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81. (Q33648339) (← links)
- Evidence that hepatitis C virus genome partly controls infection outcome. (Q33746744) (← links)
- Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement (Q33883727) (← links)
- Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections (Q34043387) (← links)
- Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem (Q34093760) (← links)
- Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles (Q34693362) (← links)
- Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks. (Q34806845) (← links)
- In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus (Q34816677) (← links)
- Broadly neutralizing antibodies abrogate established hepatitis C virus infection (Q35032263) (← links)
- Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. (Q35135565) (← links)
- Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E (Q35153978) (← links)
- Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively (Q35557115) (← links)
- A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo (Q35685409) (← links)
- Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells (Q35695028) (← links)
- Hepatitis C virus infection: establishment of chronicity and liver disease progression (Q35728873) (← links)
- Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection (Q35847032) (← links)
- Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion (Q36318779) (← links)
- Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. (Q36363320) (← links)
- Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host (Q36363966) (← links)
- Neutralizing antibodies and pathogenesis of hepatitis C virus infection (Q36395837) (← links)
- Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. (Q36745425) (← links)
- HIV and co-infections (Q36970184) (← links)
- Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation (Q36990362) (← links)
- Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease (Q37015738) (← links)
- New perspectives for preventing hepatitis C virus liver graft infection (Q37015805) (← links)
- Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. (Q37088676) (← links)
- Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host (Q37336742) (← links)
- A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81. (Q37439266) (← links)
- EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy (Q37609988) (← links)
- Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies (Q37629584) (← links)
- Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. (Q37654431) (← links)
- Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses (Q37825527) (← links)
- Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. (Q37859393) (← links)
- Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. (Q37864742) (← links)